Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Major Inclusion Criteria:~* Chronic urticaria defined as symptoms \>50% of the days or 3 days per week for more than 12 weeks~* Previous requirement for sustained or recurrent use of corticosteroids OR requirement for immunomodulatory treatment for urticaria (eg hydroxychloroquine, sulfasalazine, dapsone, cyclosporine, IVIg, etc) OR ongoing symptoms for at least 6 months duration with failure to respond at least maximally approved dosages of 2 different antihistamine therapies~* Chronic therapy with stable doses of antihistamines for at least 4 weeks. Patients may be taking more than one antihistamine or be taking combinations of antihistamines and leukotriene receptor antagonists~* High baseline score for pruritis (at least 2 on a 3 point scale)~* No underlying etiology clearly defined for urticaria~* Evidence of underlying autoimmunity as evidenced by clinical and laboratory criteria~* Concomitant use of hydroxychloroquine, sulfasalazine, or dapsone permitted if doses stable for at least 12 weeks~* Negative serum pregnancy test (for women of child-bearing age)~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment.~* No planned elective surgical procedures for at least 6 months~Major Exclusion Criteria:~* Concomitant use of corticosteroids~* Current use of immunosuppressive medication (cyclosporine, IVIg, methotrexate, cyclophosphamide). Any such medication will be discontinued for at least 6 weeks before screening.~* Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)~* Receipt of a live vaccine within 4 weeks prior to randomization~* Previous treatment with Rituximab (MabThera® / Rituxan®)~* Prior antibody therapy~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* Known history of HIV seropositivity (testing will be performed at screening)~* History of Hepatitis B and/or Hepatitis C (Hep BsAg and Hep C Ab will be obtained at screening)~* History of recurrent significant infection or history of recurrent bacterial infections~* Known active bacterial, viral, fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds)~* Any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening~* Known immunodeficiency syndrome, hypogammaglobulinemia, etc.~* Systemic lupus erythematosus~* Pregnancy (a negative serum pregnancy test will be performed for all women of childbearing potential within 7 days of treatment) or lactation~* Malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~* Atopic dermatitis~* Clinically relevant medical conditions (cardiovascular including poorly controlled hypertension or coronary artery disease, pulmonary, metabolic, renal, hepatic, psychiatric) or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications~* Plans or need to receive live viral vaccination over course of the study (e.g. Flu-Mist TM)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).